OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from โ1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
TNGX
Tango Therapeutics, Inc.
There isn't enough reported data to score TNGX yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TNGX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
TNGX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | โ |
| Current | 13x | $31.94 | โ |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TNGX PE Valuation
TNGX has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TNGX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect TNGX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TNGX on earnings quality, reporting a profit while its opponent remains loss making.
TNGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | -$0.46 |
| Q2 2026 | -$0.85 | +$0.46 |
| Q1 2026 | -$0.83 | +$0.37 |
| Q4 2025 | -$0.87 | +$0.32 |
| Q3 2025 | -$0.91 | +$0.25 |
| Q2 2025 | -$1.31 | -$0.19 |
| Q1 2025 | -$1.20 | -$0.09 |
| Q4 2024 | -$1.19 | -$0.11 |
TNGX lost $1.37 per share over the past year, a bigger loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TNGX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
TNGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $53.8M | +364% |
| Q2 2025 | $3.2M | -84% |
| Q1 2025 | $5.4M | -17% |
| Q4 2024 | $4.1M | -24% |
| Q3 2024 | $11.6M | +8.2% |
| Q2 2024 | $19.9M | +36% |
| Q1 2024 | $6.5M | +12% |
| Q4 2023 | $5.4M | -15% |
TNGX's revenue has slid since its 2025 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | 26% | +309 points |
| Q2 2025 | -1288% | -1139 points |
| Q1 2025 | -789% | -136 points |
| Q4 2024 | -994% | -349 points |
| Q3 2024 | -283% | -45 points |
| Q2 2024 | -149% | +11 points |
| Q1 2024 | -653% | -128 points |
| Q4 2023 | -645% | -168 points |
TNGX's operating margin was 26% last quarter, up 309 points from the same quarter a year ago, near the top of its range since 2020.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TNGX on cash generation, producing positive trailing cash flow while its opponent burns cash.
TNGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.2M | -$6.1M |
| Q2 2026 | -$38.9M | -$1.7M |
| Q1 2026 | -$44.4M | -$2.6M |
| Q4 2025 | -$29.9M | +$6.8M |
| Q3 2025 | -$31.1M | +$2.4M |
| Q2 2025 | -$37.1M | -$13.2M |
| Q1 2025 | -$41.7M | -$3.7M |
| Q4 2024 | -$36.8M | -$9.1M |
TNGX has burned cash in almost every quarter: โ$150M over the past year, against โ$147M the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TNGX Net Leverage
TNGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TNGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.8 | Neutral |
| Stochastic | 27.6 | Neutral |
TNGX's weekly RSI is 54 (neutral) and its Stochastic is 28 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TNGX PE vs Healthcare Sector
TNGX has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over TNGX on trend strength, trading above more of its moving averages.
TNGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.3 | 6.7% above |
| 20 week MA | $24.9 | 0% below |
| 50 week MA | $20.5 | 21% above |
| 100 week MA | $12.6 | 97% above |
| 200 week MA | $9.89 | 151% above |
TNGX's trend is mixed: it's above four of its five weekly moving averages, and 151% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to โ74% in 2021. It's up 114% so far in 2026.
TNGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $11.3 | +9.9% |
| 2021 | $11.3 | $10.9 | -2.8% |
| 2022 | $10.9 | $7.83 | -28% |
| 2023 | $7.83 | $9.90 | +26% |
| 2024 | $9.90 | $3.12 | -68% |
| 2025 | $3.12 | $8.67 | +178% |
| 2026 YTD | $8.67 | $24.9 | +187% |
TNGX has the edge over OSCR on returns for 2026, with the stronger performance.